Ingested (Oral) SIRS peptide 1-21 suppresses type 1 diabetes in NOD mice

Journal of Interferon and Cytokine Research

Volumn 28, Issue 1, 2008, Pages 25-30

  Brod, Staley A ^a   Hood, Zachary ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CELL PROTEIN; CHEMOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1; PROTEIN SIRS; RANTES; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET CELL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; CHEMOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; INFLAMMATION; ISLETS OF LANGERHANS; LYMPHOCYTES; MICE; MICE, INBRED NOD; PEPTIDE FRAGMENTS; SUPPRESSOR FACTORS, IMMUNOLOGIC;

MUS;

EID: 38649142133     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0079     Document Type: Article

References (51)

1. + T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes 55:2098-2105.
2. Atkinson MA, Maclaren NK. 1990. What causes diabetes? Sci Am 263:62-63, 66-71.
3. Aune TM, Freeman GL Jr, Colley DG. 1985. Production of the lymphokine soluble immune response suppressor (SIRS) during chronic experimental schistosomiasis mansoni. J Immunol 135:2768-2771.
4. Aune TM, Pierce CW. 1982a. Activation of a suppressor T-cell pathway by interferon. Proc Natl Acad Sci USA 79:3808-3812.
5. Aune TM, Pierce CW. 1982b. Preparation of soluble immune response suppressor and macrophage-derived suppressor factor. J Immunol Methods 43:1-14.
6. Bacon BR. 1999. Available options for treatment of interferon nonresponders. Am J Med 107:67S-70S.
7. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. 1996. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184:1101-1109.
8. Bradley LM, Asensio VC, Schioetz LK, Harbertson J, Krahl T, Patstone G, Woolf N, Campbell IL, Sarvetnick N. 1999. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 162:2511-2520.
9. Brod SA, Burns DK. 1994. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 44:1144-1148.
10. Brod S, Darcan S, Malone M, Pappolla M, Nelson L. 1998. Ingested IFN-α suppresses IDDM in the NOD mouse. Diabetologia 41:1227-1232.
11. Brod SA, Hood Z. 2007. Ingested (oral) SIRS peptide 1-21 inhibits acute EAE by inducing Th(2)-like cytokines. J Neuroimmunol 183:89-95.
12. Brod SA, Khan M. 1996. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmun 9:11-20.
13. Brod SA, Khan M, Kerman RH, Pappolla M. 1995. Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol 58:61-69.
14. Brod SA, Khan M, Nelson LD, Decuir B, Malone M, Henninger E. 2000. Adoptive transfer from interferon-alpha-fed mice is associated with inhibition of active experimental autoimmune encephalomyelitis by decreasing recipient tumor necrosis factor-alpha secretion. J Immunother 23:235-245.
15. Brod SA, Nelson L, Jin R, Wolinsky JS. 1999. Ingested interferon alpha induces Mx mRNA. Cytokine 11:492-499.
16. Brod S, Orlander P, Lavis V, Brosnan P, Hardin D, Henninger E, Nyugen M, Riley W. 2001. Ingested IFN-α prolongs the "honeymoon" period in newly diagnosed type I diabetes mellitus. J Interferon Cytokine Res 21:1021-1030.
17. Calabrese EJ. 2005. Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose-response model in the toxicological sciences. Environ Pollut 138:379-411.
18. Carvalho-Pinto C, Garcia MI, Gomez L, Ballesteros A, Zaballos A, Flores JM, Mellado M, Rodriguez-Frade JM, Balomenos D, Martinez AC. 2004. Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice. Eur J Immunol 34:548-557.
19. Castano L, Eisenbarth G. 1990. Type I diabetes: A chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 18:647-679.
20. Devens BH, Webb DR. 1995. Phenotypic identification of specific and nonspecific suppressor T-cell populations involved in the in vivo response to alloantigen. Cell Immunol 161:1-7.
21. Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SH, Radbruch A, Flesch IE, Kroczek RA. 2002. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci USA 99:6181-6186.
22. Glabinski AR, Bielecki B, Ransohoff RM. 2003. Chemokine upregulation follows cytokine expression in chronic relapsing experimental autoimmune encephalomyelitis. Scand J Immunol 58:81-88.
23. Glabinski AR, Tuohy VK, Ransohoff RM. 1998. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 5:166-171.
24. Godiska R, Chantry D, Dietsch GN, Gray PW. 1995. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 58:167-176.
25. Hanafusa T, Miyagawa J-I, Nakajima H, Tomita K, Kuwajima M, Matsuzawa Y, Tarui S. 1994. The NOD mouse. Diab Res Clin Prac 24 (Suppl):S307-311.
26. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ. 2005. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23:879-894.
27. LaFace DM, Peck AB. 1989. Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes. Diabetes 38:894-901.
28. Lampeter E, Homberg M, Quabeck K, Schaefer U, Wernet P, Bertrams J, Grosse-Wilde H, Gries F, Kolb H. 1993. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplant. Lancet 341:1243-1244.
29. Leiter E, Serreze D. 1993. Antigen presenting cells and the immunogenetics of autoimmune diabetes in NOD mice. Reg Immunol 4:263-273.
30. Lyons JA, Zhao ML, Fritz RB. 1999. Pathogenesis of acute passive murine encephalomyelitis II. Th1 phenotype of the inducing population is not sufficient to cause disease. J Neuroimmunol 93:26-36.
31. Marusic S, Miyashiro JS, Douhan J 3rd, Konz RF, Xuan D, Pelker JW, Ling V, Leonard JP, Jacobs KA. 2002. Local delivery of granulocyte macrophage colony-stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice. Neurosci Lett 332:185-189.
32. Matejuk A, Dwyer J, Ito A, Bruender Z, Vandenbark AA, Offner H. 2002. Effects of cytokine deficiency on chemokine expression in CNS of mice with EAE. J Neurosci Res 67:680-688.
33. McClive PJ, Baxter AG, Morahan G. 1994.Genetic polymorphisms of the non-obese diabetic (NOD) mouse. Immunol Cell Biol 72:137-142.
34. + T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 140:52-58.
35. Mohamadzadeh M, Poltorak AN, Bergstressor PR, Beutler B, Takashima A. 1996. Dendritic cells produce macrophage inflammatory protein-1 gamma, a new member of the CC chemokine family. J Immunol 156:3102-3106.
36. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA, et al. 1993. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 82:2975-2984.
37. Pilstrom B, Bjork L, Bohme J. 1995. Demonstration of a Th1 cytokine profile in the late phase of NOD insulinitis. Cytokine 7:806-814.
38. Sakurai T, Wakimoto N, Yamada M, Shimamura S, Motoyoshi K. 1998. Effect of macrophage colony-stimulating factor (M-CSF) on mouse immune responses in vivo. Immunopharmacol Immunotoxicol 20:79-102.
39. Schnaper HW. 1990. A regulatory system for soluble immune response suppressor production in steroid-responsive nephrotic syndrome. Kidney Int 38:151-159.
40. Schnaper HW, Aune TM. 1985. Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children. J Clin Invest 76:341-349.
41. Schnaper HW, Aune TM. 1986. Suppression of immune responses to sheep erythrocytes by the lymphokine soluble immune response suppressor (SIRS) in vivo. J Immunol 137:863-867.
42. Schnaper HW, Aune TM. 1987. Steroid-sensitive mechanism of soluble immune response suppressor production in steroid-responsive nephrotic syndrome. J Clin Invest 79:257-264.
43. Schnaper HW, Pierce CW, Aune TM. 1984. Identification and initial characterization of concanavalin A- and interferon-induced human suppressor factors: evidence for a human equivalent of murine soluble immune response suppressor (SIRS). J Immunol 132:2429-2435.
44. Serreze D, Leiter E. 1994. Genetic and pathogenic basis of autoimmune diabetes in NOD mice. Curr Opin Immunol 6:900-906.
45. Terajima C, Koontz A, Kelley M, Webb DR, Devens BH. 1990. Cytokine effects on the down regulation of cytolytic T cell responses in vitro. Lymphokine Res 9:499-506.
46. Uze G, Lutfalla G, Knudson KE. 1995. α and β Interferons and their receptor and their friends and relations. J Interferon Cytokine Res 15:3-26.
47. van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, Schrijver HM, van Houwelingen JC, Polman CH, Nagelkerken L. 2000. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann Neurol 48:313-322.
48. Webb DR, Mensi N, Freire-Moar J, Schnaper HW, Lewis RV, Semenuk G, Devens BH, Koontz A, Danho W, Pan YC, et al. 1990. Putative N-terminal sequence of murine soluble immune response suppressor (SIRS): significant homology with short neurotoxin 1. Int Immunol 2:765-774.
49. Wicker L, Todd J, Petersen L. 1995. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 13:179-200.
50. Young DA, Lowe LD, Booth SS, Whitters MJ, Nicholson L, Kuchroo VK, Collins M. 2000. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone downregulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol 164:3563-3572.
51. Zimecki M, Schnaper HW, Wieczorek Z, Webb DR, Pierce CW. 1990. Inhibition of interleukin 1 (IL-1)-elicited leukocytosis and LPS-induced fever by soluble immune response suppressor (SIRS). Immunopharmacology 19:39-46.